Stay updated with breaking news from Julia Foldi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.
Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.
Among younger women with breast cancer, it may be possible for many to have a baby after their diagnosis, new research suggests.
UPMC and University of Pittsburgh researchers will test a vaccine to prevent breast cancer in what they say is a revolutionary step in the fight against the most common cancer in women. The seed money — $100,000 — to launch the clinical trial came from the Wexford-based nonprofit, Glimmer of
Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) and non-AA patients.